Wall Street View Pharmaceutical Executives’ 2013 © yright ibution p istr Co l D nload, rcia n dow Pipelinem Re eeprs caort m us use Co orised sonal or . Auth or per ale hibited copy f r S se pro ingle t fo ised u rint a s AlzhNeimoer’s Daiustehaosre: Movi nangd F porward Un y, view displa Drug Name Company Phase Launch Date Sales Potential Solanezumab III N/A N/A Gantenerumab II/III N/A N/A
Hepatitis C: The More the Merrier
Drug Name Company Phase Launch Date Sales Potential Sofosbuvir III 2014 Blockbuster Simeprevir/Daclatasvir III 2014/2015 Minibuster
ABT-450 III 2015 Blockbuster
Setrobuvir/Danoprevir/ II 2015 Minibuster Mericitabine Sovaprevir II N/A N/A
Rheumatoid Arthritis: Return of the DMARDS
Drug Name Company Phase Launch Date Sales Potential Tofacitinib Preregistration 2012/2013 Blockbuster Baricitinib II N/A N/A
Fostamatinib III 2014 Minibuster
GLPG 0634 II 2017 N/A
Canadian Pharmaceutical Marketing l June/July 2013 7 Wall Street View
Cancer: Improving on Innovation
Drug Name Company Phase Launch Date Sales Potential GDC-0973 III N/A N/A
Dabrafenib Preregistered 2013 Minibuster
Trametinib Preregistered 2013 Minibuster
Nivolumab II 2015 Blockbuster
Trastuzumab Emtansine Preregistration 2013 Blockbuster
3 Radium-223 Chloride III N/A Blockbuster
ARN 509 I/II N/A N/A
Ponatinib Preregistration 2013 Minibuster
Ibrutinib III 2014 Blockbuster
Diabetes: Incremental Improvement
Drug Name Company Phase Launch Date Sales Potential Tresiba Preregistered 2013 Blockbuster
Ryzodeg Preregistered 2013 Blockbuster
LY2605541 & LY2963016 III 2015 Blockbuster
Canagliflozin Preregistration 2014 Blockbuster
8 Canadian Pharmaceutical Marketing l June/July 2013 Wall Street View
Hyperlipidemia: CETP Inhibitors, PCSK9 Inhibitors, and More
Drug Name Company Phase Launch Date Sales Potential Alirocumab III 2016 Blockbuster
AMG 145 III 2016 Blockbuster
Anacetrapib III 2016 Blockbuster
Multiple Sclerosis: We’ve Got Your Number
Drug Name Company Phase Launch Date Sales Potential Lemtrada Preregistered 2013 Minibuster
Laquinimod III 2015 Minibuster
Top Therapeutic Areas by Late-stage Products
Therapeutic Category Estimated Global Sales 2018 ($US million) Oncology and Immunomodulators 16,668 Central Nervous System 13,891 Systemic Anti-infectives 13,600 Endocrine 7,627 Cardiovascular 5,794 Musculoskeletal 5,647 Respiratory 2,938 Blood 2,386 Late-stage includes Phase III and Filed Forecast data courtesy of EvaluatePharma
* Source: Adapted from Pharmaceutical Executive “Pharm Exec’s 2013 Pipeline Report,” written by Ben Comer, Senior Editor, November 2012; Volume 32, Number 11. CPM
Canadian Pharmaceutical Marketing l June/July 2013 9